EcoDrugPlus

C-Reactive Protein

Ensembl ID : ENSXETG00000038688
Gene Symbol: LOC100487769
4 View Cross-references
555 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-Reactive Protein

Ensembl ID : ENSXETG00000030596
Gene Symbol: LOC100489587
5 View Cross-references
555 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-Reactive Protein, Pentraxin-Related, Gene 1

Ensembl ID : ENSXETG00000003976
Gene Symbol: CRP.1
5 View Cross-references
545 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-Reactive Protein, Pentraxin-Related, Gene 2

Ensembl ID : ENSXETG00000037720
Gene Symbol: LOC100486739
3 View Cross-references
545 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-Reactive Protein, Pentraxin-Related, Gene 4

Ensembl ID : ENSXETG00000027272
Gene Symbol: MGC107876
6 Enzyme and pathways 5 View Cross-references
555 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cckbr Cholecystokinin B Receptor

Ensembl ID : ENSXETG00000048557
Gene Symbol: CCKBR
7 Enzyme and pathways 5 View Cross-references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Methyltransferase 1

Ensembl ID : ENSXETG00000022035
Gene Symbol: DNMT1
8 Enzyme and pathways 5 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase I, Gene 1

Ensembl ID : ENSXETG00000040254
Gene Symbol: TOP1.1
5 Enzyme and pathways 5 View Cross-references
271 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSXETG00000021362
Gene Symbol: TOP2A
5 Enzyme and pathways 5 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase Ii Beta

Ensembl ID : ENSXETG00000007282
Gene Symbol: TOP2B
5 Enzyme and pathways 5 View Cross-references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Eph Receptor A2

Ensembl ID : ENSXETG00000047004
Gene Symbol: EPHA2
5 View Cross-references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Eph Receptor A3

Ensembl ID : ENSXETG00000020173
Gene Symbol: EPHA3
6 Enzyme and pathways 5 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).